AU2005275009B2 - Apolipoprotein A1 mimetics and uses thereof - Google Patents

Apolipoprotein A1 mimetics and uses thereof Download PDF

Info

Publication number
AU2005275009B2
AU2005275009B2 AU2005275009A AU2005275009A AU2005275009B2 AU 2005275009 B2 AU2005275009 B2 AU 2005275009B2 AU 2005275009 A AU2005275009 A AU 2005275009A AU 2005275009 A AU2005275009 A AU 2005275009A AU 2005275009 B2 AU2005275009 B2 AU 2005275009B2
Authority
AU
Australia
Prior art keywords
peptidomimetic
subject
amino acid
cholesterol
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005275009A
Other languages
English (en)
Other versions
AU2005275009A1 (en
Inventor
William W. Bachovchin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of AU2005275009A1 publication Critical patent/AU2005275009A1/en
Assigned to TRUSTEES OF TUFTS COLLEGE reassignment TRUSTEES OF TUFTS COLLEGE Alteration of Name(s) of Applicant(s) under S113 Assignors: KOS LIFE SCIENCES, INC., TRUSTEES OF TUFTS COLLEGE
Application granted granted Critical
Publication of AU2005275009B2 publication Critical patent/AU2005275009B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2005275009A 2004-07-16 2005-07-15 Apolipoprotein A1 mimetics and uses thereof Ceased AU2005275009B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58872204P 2004-07-16 2004-07-16
US60/588,722 2004-07-16
PCT/US2005/025182 WO2006020040A2 (en) 2004-07-16 2005-07-15 Apolipoprotein a1 mimetics and uses thereof

Publications (2)

Publication Number Publication Date
AU2005275009A1 AU2005275009A1 (en) 2006-02-23
AU2005275009B2 true AU2005275009B2 (en) 2011-12-08

Family

ID=35907926

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005275009A Ceased AU2005275009B2 (en) 2004-07-16 2005-07-15 Apolipoprotein A1 mimetics and uses thereof

Country Status (12)

Country Link
US (3) US7569546B2 (cg-RX-API-DMAC10.html)
EP (1) EP1771473B1 (cg-RX-API-DMAC10.html)
JP (1) JP5048486B2 (cg-RX-API-DMAC10.html)
KR (1) KR101185609B1 (cg-RX-API-DMAC10.html)
CN (1) CN101076541A (cg-RX-API-DMAC10.html)
AU (1) AU2005275009B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0513402A (cg-RX-API-DMAC10.html)
CA (1) CA2574007A1 (cg-RX-API-DMAC10.html)
IL (1) IL180733A (cg-RX-API-DMAC10.html)
NO (1) NO20070876L (cg-RX-API-DMAC10.html)
TW (1) TWI377066B (cg-RX-API-DMAC10.html)
WO (1) WO2006020040A2 (cg-RX-API-DMAC10.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
JP5048486B2 (ja) * 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
KR20070089996A (ko) * 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AU2006242651B2 (en) * 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
EP2049137A4 (en) * 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
ATE533783T1 (de) 2006-12-13 2011-12-15 Univ California Potente und selektive mittlersubstanzen von cholesterolefflux
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009036460A2 (en) * 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) * 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US20110020242A1 (en) * 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
MX2011008599A (es) * 2009-02-16 2011-11-18 Cerenis Therapeutics Sa Peptidos mimeticos de la apolipoproteina a-i.
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
US20130310304A1 (en) * 2010-06-15 2013-11-21 Matthew C. Lawyer Compositions and methods for the treatment of atherosclerosis
LT2673296T (lt) * 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN103910802B (zh) * 2014-04-24 2017-01-11 华中科技大学 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
FR3026409B1 (fr) * 2014-09-26 2018-03-30 Centre National De La Recherche Scientifique (Cnrs) Procede de criblage de molecules interferentes
AU2016238290B9 (en) 2015-03-25 2019-06-13 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
AU2018210404B2 (en) * 2017-01-19 2022-01-27 Novo Nordisk A/S ApoC-II mimetic peptides
KR20260012291A (ko) 2018-07-12 2026-01-26 더 리젠츠 오브 더 유니버시티 오브 미시간 면역 반응을 조절할 수 있는 금속 함유 제형의 조성물 및 방법
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
CA3197168A1 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3216226A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
US20250230208A1 (en) 2022-04-06 2025-07-17 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3258787A1 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
KR20260010675A (ko) 2023-01-13 2026-01-21 아비오닉스 파마 에스에이 지질 결합 단백질 분자 치료
IL327995A (en) 2023-10-31 2026-06-01 Abionyx Pharma Sa Lipid binding protein molecule therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045460A1 (en) * 2000-08-24 2003-03-06 Fogelman Alan M. Orally administered peptides to ameliorate atherosclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US7105635B2 (en) * 2002-06-04 2006-09-12 The University Of Toledo Cyclic beta-sheet peptides useful as apoptotic/cytotoxic cancer agents
JP5048486B2 (ja) * 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
KR20070089996A (ko) * 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045460A1 (en) * 2000-08-24 2003-03-06 Fogelman Alan M. Orally administered peptides to ameliorate atherosclerosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Circulation, 2002, 105, 290-292. *

Also Published As

Publication number Publication date
US20120259091A1 (en) 2012-10-11
TWI377066B (en) 2012-11-21
TW200612977A (en) 2006-05-01
IL180733A (en) 2013-01-31
JP5048486B2 (ja) 2012-10-17
US8124580B2 (en) 2012-02-28
WO2006020040A2 (en) 2006-02-23
JP2008506709A (ja) 2008-03-06
NO20070876L (no) 2007-03-30
BRPI0513402A (pt) 2008-05-06
CN101076541A (zh) 2007-11-21
EP1771473B1 (en) 2012-12-26
KR101185609B1 (ko) 2012-09-24
US7569546B2 (en) 2009-08-04
US20060069030A1 (en) 2006-03-30
EP1771473A2 (en) 2007-04-11
IL180733A0 (en) 2007-06-03
AU2005275009A1 (en) 2006-02-23
WO2006020040A3 (en) 2006-07-06
CA2574007A1 (en) 2006-02-23
KR20070095862A (ko) 2007-10-01
US20100009919A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
EP1771473B1 (en) Apolipoprotein a1 mimetics and uses thereof
AU2004264944B2 (en) Orally administered small peptides synergize statin activity
US8048851B2 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AU2006242651B2 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
RU2448977C2 (ru) Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью
US20080293639A1 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ZA200601638B (en) Orally administered small peptides synergize statin activity
MX2007000571A (en) Apolipoprotein a1 mimetics and uses thereof
HK1147696A (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: REMOVE THE CO-INVENTOR EUGENIO A. CEFALI

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired